{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:36:52Z","timestamp":1770813412424,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.ppat.1013923","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000}}],"reference-count":74,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI164560"],"award-info":[{"award-number":["UM1AI164560"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1149990"],"award-info":[{"award-number":["APP1149990"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1135851"],"award-info":[{"award-number":["APP1135851"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2026490"],"award-info":[{"award-number":["APP2026490"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009781","name":"ACH2","doi-asserted-by":"crossref","award":["825843"],"award-info":[{"award-number":["825843"]}],"id":[{"id":"10.13039\/100009781","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009781","name":"ACH2","doi-asserted-by":"crossref","award":["ACH2_2022_APP_Kim"],"award-info":[{"award-number":["ACH2_2022_APP_Kim"]}],"id":[{"id":"10.13039\/100009781","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>\n                    The persistence of latently infected CD4\u2009+\u2009T-cells in people with HIV (PWH) on suppressive antiretroviral therapy (ART) is the major barrier to an HIV cure. We investigated the impact of two classes of pro-apoptotic drugs, phosphoinositide-3 kinases (PI3K) inhibitors or the B cell lymphoma 2 (Bcl-2) inhibitor venetoclax on depletion of latently infected CD4\u2009+\u2009T-cells when administered\n                    <jats:italic>ex vivo<\/jats:italic>\n                    either alone or in combination with a latency reversing agents (LRA) to induce expression of pro-apoptotic viral proteins. We quantified cell death in three latently infected cell lines (J-Lat clones) and the parental cell line (Jurkat) using a live dead stain and flow cytometry. Using CD4\u2009+\u2009T-cells isolated from blood from PWH on ART, we quantified intracellular HIV RNA, integrated HIV DNA and intact proviral DNA using quantitative PCR. In the Jat10.6 latently infected cell line, the combination of an LRA with either a PI3K inhibitor or venetoclax, compared to an LRA alone resulted in higher levels of cell death. Using CD4\u2009+\u2009T-cells from PWH on ART, there was a significant decrease in HIV DNA following administration of wortmannin (a pan-PI3K inhibitor), venetoclax (a Bcl2 inhibitor) and JQ1 (an LRA) when administered alone. There was minimal additional effect on reservoir reduction following the addition of an LRA with a pro-apoptotic drug, compared to either an LRA or pro-apoptotic drug alone. However, when CD4\u2009+\u2009T-cells from PWH on ART were treated with LRAs combined with a PI3K inhibitor, the fold increase in cell associated unspliced HIV RNA correlated with the decline in HIV DNA. Overall, reduction in the HIV reservoir by LRAs could be further enhanced in the presence of pro-apoptotic drugs, but the magnitude of the effect was modest, was dependent on the\n                    <jats:italic>in vitro<\/jats:italic>\n                    model used and for PI3K inhibitors, depended on the potency of latency reversal. These results are consistent with minimal additional efficacy in reservoir reduction when combining currently available LRAs and either PI3K inhibitors or venetoclax.\n                  <\/jats:p>","DOI":"10.1371\/journal.ppat.1013923","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T18:35:17Z","timestamp":1769711717000},"page":"e1013923","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of combining HIV latency reversal with inhibition of phosphoinositide-3 kinases or B-cell lymphoma-2 on the HIV reservoir"],"prefix":"10.1371","volume":"22","author":[{"given":"Youry","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Tumpach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajantha","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesslyn","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiho","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Zerbato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charis E.","family":"Teh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel H. D.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Arandjelovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niamh","family":"Meagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0330-8241","authenticated-orcid":true,"given":"Sharon R.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"issue":"5341","key":"ppat.1013923.ref001","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"D Finzi","year":"1997","journal-title":"Science"},{"issue":"4","key":"ppat.1013923.ref002","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1084\/jem.20170193","article-title":"Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: potential role in latent reservoir dynamics","volume":"214","author":"NN Hosmane","year":"2017","journal-title":"J Exp Med"},{"issue":"5","key":"ppat.1013923.ref003","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/jmp.12613","article-title":"The role of latency reversal in HIV cure strategies","volume":"51","author":"K Tanaka","year":"2022","journal-title":"J Med Primatol"},{"issue":"7408","key":"ppat.1013923.ref004","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature11286","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy","volume":"487","author":"NM Archin","year":"2012","journal-title":"Nature"},{"issue":"10","key":"ppat.1013923.ref005","article-title":"Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy","volume":"10","author":"JH Elliott","year":"2014","journal-title":"PLoS Pathog"},{"issue":"12","key":"ppat.1013923.ref006","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(15)00226-X","article-title":"Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study","volume":"2","author":"JH Elliott","year":"2015","journal-title":"Lancet HIV"},{"issue":"9","key":"ppat.1013923.ref007","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1097\/QAD.0000000000001064","article-title":"Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy","volume":"30","author":"C Guti\u00e9rrez","year":"2016","journal-title":"AIDS"},{"issue":"1","key":"ppat.1013923.ref008","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial","volume":"1","author":"TA Rasmussen","year":"2014","journal-title":"Lancet HIV"},{"issue":"9","key":"ppat.1013923.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005142","article-title":"The depsipeptide romidepsin reverses HIV-1 latency in vivo","volume":"11","author":"OS S\u00f8gaard","year":"2015","journal-title":"PLoS Pathog"},{"issue":"3","key":"ppat.1013923.ref010","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(21)00239-1","article-title":"Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial","volume":"3","author":"H Gruell","year":"2022","journal-title":"Lancet Microbe"},{"issue":"4","key":"ppat.1013923.ref011","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"S Elmore","year":"2007","journal-title":"Toxicol Pathol"},{"issue":"1","key":"ppat.1013923.ref012","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"PE Czabotar","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"ppat.1013923.ref013","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s10637-013-0002-4","article-title":"Bcl-2 antagonists: a proof of concept for CLL therapy","volume":"31","author":"K Balakrishnan","year":"2013","journal-title":"Invest New Drugs"},{"issue":"2","key":"ppat.1013923.ref014","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"AJ Souers","year":"2013","journal-title":"Nat Med"},{"issue":"25","key":"ppat.1013923.ref015","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","article-title":"The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism","volume":"127","author":"MA Anderson","year":"2016","journal-title":"Blood"},{"key":"ppat.1013923.ref016","article-title":"BCL-2 antagonism decreases HIV replication and infected cell survival in acute in vitro infection","author":"N Cummins","year":"2016","journal-title":"IAS 2016 Towards an HIV Cure Symposium; Durban, South Africa"},{"issue":"5","key":"ppat.1013923.ref017","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1172\/JCI132374","article-title":"BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo","volume":"130","author":"Y Ren","year":"2020","journal-title":"J Clin Invest"},{"issue":"9","key":"ppat.1013923.ref018","doi-asserted-by":"crossref","first-page":"101178","DOI":"10.1016\/j.xcrm.2023.101178","article-title":"Venetoclax, alone and in combination with the BH3 mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized mice","volume":"4","author":"P Arandjelovic","year":"2023","journal-title":"Cell Rep Med"},{"issue":"4","key":"ppat.1013923.ref019","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1099\/jgv.0.000402","article-title":"Modulation of apoptosis and viral latency - an axis to be well understood for successful cure of human immunodeficiency virus","volume":"97","author":"U Timilsina","year":"2016","journal-title":"J Gen Virol"},{"issue":"1","key":"ppat.1013923.ref020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"LM Thorpe","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"6759","key":"ppat.1013923.ref021","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/46319","article-title":"Structural insights into phosphoinositide 3-kinase catalysis and signalling","volume":"402","author":"EH Walker","year":"1999","journal-title":"Nature"},{"key":"ppat.1013923.ref022","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1099\/vir.0.19771-0","article-title":"The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival","volume":"85","author":"S Cooray","year":"2004","journal-title":"J Gen Virol"},{"key":"ppat.1013923.ref023","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1742-4690-5-11","article-title":"Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy","volume":"5","author":"P Chugh","year":"2008","journal-title":"Retrovirology"},{"issue":"9","key":"ppat.1013923.ref024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013121","article-title":"Targeting the PI3K\/Akt cell survival pathway to induce cell death of HIV-1 infected macrophages with alkylphospholipid compounds","volume":"5","author":"A Lucas","year":"2010","journal-title":"PLoS One"},{"issue":"7","key":"ppat.1013923.ref025","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1128\/JVI.74.7.3105-3111.2000","article-title":"Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation","volume":"74","author":"SA Stewart","year":"2000","journal-title":"J Virol"},{"issue":"13","key":"ppat.1013923.ref026","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1128\/JVI.02798-06","article-title":"Human immunodeficiency virus type 1 protease cleaves procaspase 8 in vivo","volume":"81","author":"Z Nie","year":"2007","journal-title":"J Virol"},{"key":"ppat.1013923.ref027","first-page":"1","article-title":"HIV protease cleavage of procaspase 8 is necessary for death of HIV-infected cells","volume":"2","author":"Z Nie","year":"2008","journal-title":"Open Virol J"},{"issue":"8","key":"ppat.1013923.ref028","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1128\/JVI.03179-15","article-title":"Prime, shock, and kill: priming CD4 T cells from HIV patients with a BCL-2 antagonist before HIV reactivation reduces HIV reservoir size","volume":"90","author":"NW Cummins","year":"2016","journal-title":"J Virol"},{"issue":"6","key":"ppat.1013923.ref029","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/9498","article-title":"Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy","volume":"5","author":"TW Chun","year":"1999","journal-title":"Nat Med"},{"issue":"17","key":"ppat.1013923.ref030","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1097\/00002030-199912030-00012","article-title":"Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy","volume":"13","author":"JM Prins","year":"1999","journal-title":"AIDS"},{"issue":"2","key":"ppat.1013923.ref031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008151","article-title":"Diverse effects of interferon alpha on the establishment and reversal of HIV latency","volume":"16","author":"RM Van der Sluis","year":"2020","journal-title":"PLoS Pathog"},{"issue":"13","key":"ppat.1013923.ref032","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1182\/blood-2007-06-097907","article-title":"CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency","volume":"110","author":"S Saleh","year":"2007","journal-title":"Blood"},{"issue":"21","key":"ppat.1013923.ref033","doi-asserted-by":"crossref","first-page":"12385","DOI":"10.1128\/JVI.00609-14","article-title":"Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies","volume":"88","author":"C Vandergeeten","year":"2014","journal-title":"J Virol"},{"issue":"10","key":"ppat.1013923.ref034","doi-asserted-by":"crossref","first-page":"100766","DOI":"10.1016\/j.xcrm.2022.100766","article-title":"Memory CD4(+) T cells that co-express PD1 and CTLA4 have reduced response to activating stimuli facilitating HIV latency","volume":"3","author":"TA Rasmussen","year":"2022","journal-title":"Cell Rep Med"},{"key":"ppat.1013923.ref035","doi-asserted-by":"crossref","first-page":"103241","DOI":"10.1016\/j.ebiom.2021.103241","article-title":"Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency","volume":"65","author":"JM Zerbato","year":"2021","journal-title":"EBioMedicine"},{"issue":"7742","key":"ppat.1013923.ref036","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","article-title":"A quantitative approach for measuring the reservoir of latent HIV-1 proviruses","volume":"566","author":"KM Bruner","year":"2019","journal-title":"Nature"},{"issue":"2","key":"ppat.1013923.ref037","doi-asserted-by":"crossref","first-page":"100335","DOI":"10.1016\/j.jve.2023.100335","article-title":"Adaptation of the intact proviral DNA assay to a nanowell-based digital PCR platform","volume":"9","author":"C Tumpach","year":"2023","journal-title":"J Virus Erad"},{"issue":"7","key":"ppat.1013923.ref038","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1038\/s41418-020-0498-z","article-title":"Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells","volume":"27","author":"CE Teh","year":"2020","journal-title":"Cell Death Differ"},{"issue":"5","key":"ppat.1013923.ref039","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1172\/JCI80142","article-title":"Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations","volume":"125","author":"GM Laird","year":"2015","journal-title":"J Clin Invest"},{"issue":"12","key":"ppat.1013923.ref040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003834","article-title":"An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients","volume":"9","author":"CA Spina","year":"2013","journal-title":"PLoS Pathog"},{"issue":"8","key":"ppat.1013923.ref041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007991","article-title":"Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations","volume":"15","author":"J Grau-Exp\u00f3sito","year":"2019","journal-title":"PLoS Pathog"},{"issue":"1","key":"ppat.1013923.ref042","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12977-016-0325-2","article-title":"HIV integration sites in latently infected cell lines: evidence of ongoing replication","volume":"14","author":"J Symons","year":"2017","journal-title":"Retrovirology"},{"issue":"4","key":"ppat.1013923.ref043","article-title":"Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing","volume":"10","author":"DG Wei","year":"2014","journal-title":"PLoS Pathog"},{"issue":"8","key":"ppat.1013923.ref044","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/emboj\/cdg188","article-title":"HIV reproducibly establishes a latent infection after acute infection of T cells in vitro","volume":"22","author":"A Jordan","year":"2003","journal-title":"EMBO J"},{"issue":"11","key":"ppat.1013923.ref045","doi-asserted-by":"crossref","first-page":"8207","DOI":"10.1074\/jbc.M606324200","article-title":"Identifying the membrane proteome of HIV-1 latently infected cells","volume":"282","author":"R Berro","year":"2007","journal-title":"J Biol Chem"},{"issue":"1","key":"ppat.1013923.ref046","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bbapap.2007.10.003","article-title":"Targeting phosphoinositide 3-kinase: moving towards therapy","volume":"1784","author":"R Marone","year":"2008","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"ppat.1013923.ref047","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly1","volume":"26","author":"CI Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"issue":"10","key":"ppat.1013923.ref048","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.83","article-title":"Romidepsin targets multiple survival signaling pathways in malignant T cells","volume":"5","author":"BC Valdez","year":"2015","journal-title":"Blood Cancer J"},{"issue":"7","key":"ppat.1013923.ref049","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","article-title":"FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma","volume":"21","author":"BW Miller","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"3","key":"ppat.1013923.ref050","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/jcp.26135","article-title":"Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia","volume":"233","author":"C Evangelisti","year":"2018","journal-title":"J Cell Physiol"},{"issue":"35","key":"ppat.1013923.ref051","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"M Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"ppat.1013923.ref052","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-018-4792-0","article-title":"Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy","volume":"171","author":"S Jain","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"ppat.1013923.ref053","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2055-6640(20)30042-X","article-title":"Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation","volume":"5","author":"JD Gunst","year":"2019","journal-title":"J Virus Erad"},{"issue":"25","key":"ppat.1013923.ref054","doi-asserted-by":"crossref","first-page":"22211","DOI":"10.1074\/jbc.M110.180224","article-title":"Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells","volume":"286","author":"K Huber","year":"2011","journal-title":"J Biol Chem"},{"issue":"11","key":"ppat.1013923.ref055","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1074\/jbc.M807898200","article-title":"Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells","volume":"284","author":"X Contreras","year":"2009","journal-title":"J Biol Chem"},{"issue":"1","key":"ppat.1013923.ref056","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.1995.tb08915.x","article-title":"Tat-expressing Jurkat cells show an increased resistance to different apoptotic stimuli, including acute human immunodeficiency virus-type 1 (HIV-1) infection","volume":"89","author":"D Gibellini","year":"1995","journal-title":"Br J Haematol"},{"issue":"11","key":"ppat.1013923.ref057","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1111\/cas.12002","article-title":"Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase\/phosphatidylinositol 3-kinase dual inhibitors","volume":"103","author":"K Saijo","year":"2012","journal-title":"Cancer Sci"},{"issue":"3","key":"ppat.1013923.ref058","first-page":"477","article-title":"Suppression of phosphatidylinositol 3-kinase\/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells","volume":"13","author":"M Kodani","year":"2005","journal-title":"Oncol Rep"},{"issue":"19","key":"ppat.1013923.ref059","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/blood-2017-06-792150","article-title":"Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients","volume":"130","author":"BM Cyrenne","year":"2017","journal-title":"Blood"},{"issue":"9","key":"ppat.1013923.ref060","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nmeth.4380","article-title":"Simultaneous epitope and transcriptome measurement in single cells","volume":"14","author":"M Stoeckius","year":"2017","journal-title":"Nat Methods"},{"issue":"12","key":"ppat.1013923.ref061","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00138-21","article-title":"The combination of venetoclax and ixazomib selectively and efficiently kills HIV-infected cell lines but has unacceptable toxicity in primary cell models","volume":"95","author":"A Alto","year":"2021","journal-title":"J Virol"},{"issue":"13","key":"ppat.1013923.ref062","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00037-18","article-title":"HIV protease-generated Casp8p41, when bound and inactivated by Bcl2, is degraded by the proteasome","volume":"92","author":"S Natesampillai","year":"2018","journal-title":"J Virol"},{"issue":"3","key":"ppat.1013923.ref063","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure","volume":"155","author":"Y-C Ho","year":"2013","journal-title":"Cell"},{"issue":"9","key":"ppat.1013923.ref064","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.4156","article-title":"Defective proviruses rapidly accumulate during acute HIV-1 infection","volume":"22","author":"KM Bruner","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"ppat.1013923.ref065","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1038\/s41467-018-05899-7","article-title":"HIV-1 intron-containing RNA expression induces innate immune activation and T cell dysfunction","volume":"9","author":"H Akiyama","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"ppat.1013923.ref066","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.cell.2010.11.001","article-title":"Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue","volume":"143","author":"G Doitsh","year":"2010","journal-title":"Cell"},{"issue":"7","key":"ppat.1013923.ref067","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1073\/pnas.1917876117","article-title":"Defective HIV-1 proviruses produce viral proteins","volume":"117","author":"H Imamichi","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"ppat.1013923.ref068","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1172\/JCI124291","article-title":"Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy","volume":"129","author":"KB Einkauf","year":"2019","journal-title":"J Clin Invest"},{"issue":"4","key":"ppat.1013923.ref069","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132997","article-title":"Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy","volume":"5","author":"MJ Peluso","year":"2020","journal-title":"JCI Insight"},{"issue":"1","key":"ppat.1013923.ref070","doi-asserted-by":"crossref","first-page":"9966","DOI":"10.1038\/s41467-024-54116-1","article-title":"Rapid biphasic decay of intact and defective HIV DNA reservoir during acute treated HIV disease","volume":"15","author":"A Barbehenn","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"ppat.1013923.ref071","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/diseases13060179","article-title":"Sex differences in immune responses to infectious diseases: the role of genetics, hormones, and aging","volume":"13","author":"P Rio","year":"2025","journal-title":"Diseases"},{"issue":"7947","key":"ppat.1013923.ref072","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41586-022-05556-6","article-title":"HIV silencing and cell survival signatures in infected T cell reservoirs","volume":"614","author":"IC Clark","year":"2023","journal-title":"Nature"},{"issue":"7947","key":"ppat.1013923.ref073","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41586-022-05538-8","article-title":"Phenotypic signatures of immune selection in HIV-1 reservoir cells","volume":"614","author":"W Sun","year":"2023","journal-title":"Nature"},{"issue":"1","key":"ppat.1013923.ref074","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1038\/s41467-025-60001-2","article-title":"Efficient mRNA delivery to resting T cells to reverse HIV latency","volume":"16","author":"PM Cevaal","year":"2025","journal-title":"Nat Commun"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1013923","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1013923","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:51:59Z","timestamp":1770403919000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1013923"}},"subtitle":[],"editor":[{"given":"Richard A.","family":"Koup","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1013923","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}